13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Neuropharmacology and Novel Drug Development
The field of neuropharmacology and novel drug development delves into the biochemical pathways and molecular targets underlying neurological function and dysfunction. This research area is pivotal in driving the creation of innovative drugs, ranging from neuroprotective agents to neuromodulators. Advanced methodologies, such as CRISPR-based genome editing and nanotechnology, are transforming the delivery and effectiveness of neurotherapeutics. Researchers are also focusing on strategies to overcome the challenges of the blood-brain barrier, ensuring enhanced drug delivery to the central nervous system. With a strong focus on addressing unmet clinical needs, neuropharmacology is expanding the frontiers of science, paving the way for groundbreaking solutions to neurological and psychiatric disorders.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : ADNP regulates cortical development: Mechanism of ADNP syndrome/autism
Kazuhito Toyooka, Drexel University College of Medicine, United States
Title : Mild cognitive impairment (MCI) in Parkinson’s disease: Prevalence given MDS criteria
Cay Anderson Hanley, iPACES, United States
Title : Modeling early neurologic trajectories after elevated leg positioning (ELP): A secondary analysis of the LEG-UP randomized feasibility study
Kayode Ahmed, The University of Texas MD Anderson Cancer Center, United States
Title : Neuro-exergaming for non-verbal autism spectrum: A case study of neuropsychological function after 15 sessions of pedal-n-play iPACES
Cay Anderson Hanley, iPACES, United States
Title : Prescribing joy: The importance of integrating memory cafes into dementia care
Saul Beaumont, Massachusetts Advisory Council on Alzheimer's Disease and All Other Dementias, United States